Prevalence of sodium disorders in COVID-19 patients [COVID-19]

  • Research type

    Research Study

  • Full title

    Prevalence of sodium disorders among hospitalised COVID-19 patients

  • IRAS ID

    286385

  • Contact name

    Stephanie Baldeweg

  • Contact email

    stephanie.baldeweg@nhs.net

  • Sponsor organisation

    University College London Hospitals

  • Duration of Study in the UK

    0 years, 1 months, 1 days

  • Research summary

    During the current worldwide pandemic, millions of people have been reported to be infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. Sodium imbalance is one of the commonest electroless disorders encountered in medical practice. There is no data about the prevalence of sodium disorders and its use as a marker of disease severity in patients with Covid-19. There is the potential for serum Na values to be used as a predictor of severe clinical course and be used as part of risk stratification scores and guide clinical decision-making. There is very little available data about serum Na in cases infected by SARS-CoV-2. The primary aim of this study is top investigate the prevalence of sodium disorders in patients with COVID-19 infection and to evaluate the role of serum sodium as a predictor of severe disease, need for ICU admission and mechanical ventilation, and mortality.

  • REC name

    N/A

  • REC reference

    N/A